Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 17/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10843117 | 0.85 | CASP1 (1.00) | CASP1MAPT | |
| SCHEMBL5899777 | 0.78 | CASP1 (1.00) | CASP1MAPTALDH1A1 | |
| SCHEMBL11394221 | 0.73 | PIK3CD (0.49) | CASP1 | |
| SCHEMBL580314 | 0.72 | CASP1 (0.76) | CASP1DHODHALDH1A1 | |
| SCHEMBL30277756 | 0.72 | CASP1 (1.00) | CASP1 | |
| SCHEMBL8541795 | 0.72 | CASP1 (0.62) | CASP1ALDH1A1 | |
| SCHEMBL5899792 | 0.72 | CASP1 (1.00) | CASP1 | |
| SCHEMBL8541788 | 0.72 | CASP1 (0.62) | CASP1MAPTALDH1A1 | |
| SCHEMBL5899769 | 0.71 | CASP1 (0.54) | CASP1MAPTDHODHALDH1A1GAA | |
| SCHEMBL30833982 | 0.70 | ALDH1A1 (0.44) | CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995261-B2 | 4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | disclosed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | disclosed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | IL6ST, IL1RN, IL1R1 | CASP1 117/4885MAPT 4281/4885DHODH 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.